The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Butyrate-Producing Probiotics Reduce Nonalcoholic Fatty Liver Disease Progression in Rats: New Insight into the Probiotics for the Gut-Liver Axis
Open accessAbstract
Nonalcoholic fatty liver disease (NAFLD) includes simple steatosis, nonalcoholic steatohepatitis (NASH), fibrosis, cirrhosis, and hepatocellular carcinoma. The gut-derived endotoxin plays an essential role in the pathophysiological development and progression of NAFLD. By using rat models of choline-deficient/L-amino acid-defined (CDAA)-diet-induced NAFLD, we examined whether MIYAIRI 588--a butyrate-producing probiotic--prevents the progression of pathophysiological changes from steatosis to hepatocarcinogenesis. In vivo experiments showed that treatment with MIYAIRI 588 reduced CDAA-diet-induced hepatic lipid deposition and significantly improved the triglyceride content, insulin resistance, serum endotoxin levels, and hepatic inflammatory indexes. We also found that MIYAIRI 588 substantially increased the activation of hepatic adenosine 5'-monophosphate-activated protein kinase (AMPK) and AKT and the expression of lipogenesis- or lipolysis-related proteins. MIYAIRI 588 also improved CDAA-diet-induced delocalization and substantially decreased the expression of the tight-junction proteins intestinal zonula occluden-1 and occludin in CDAA-diet-fed rats. Further, the MIYAIRI 588-treated rats also showed remarkable induction of nuclear factor erythoid 2-related factor 2 (Nrf2) and its targeted antioxidative enzymes, which suppressed hepatic oxidative stress. In vitro studies revealed that treatment with sodium butyrate (NaB) also activated AMPK and AKT and enhanced Nrf2 expression by precluding ubiquitination, thereby increasing the half-life of the Nrf2 protein. Pharmacological studies and siRNA knockdown experiments showed that NaB-mediated AMPK activation induced the phosphorylation and nuclear translocation of Sirtuin 1, leading to the increased assembly of mammalian TOR complex 2 and phosphorylation of AKT at Ser473 and subsequent induction of Nrf2 expression and activation. These favorable changes caused an obvious decrease in hepatic fibrous deposition, GST-P-positive foci development, and hepatocarcinogenesis. Our data clearly established that the probiotic MIYAIRI 588 has beneficial effects in the prevention of NAFLD progression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matthews, D. R., Hosker, J. P., Rudenski, A. S., Naylor, B. A., Treacher, D. F., & Turner, R. C. (1985) · Diabetologia · doi:10.1007/bf00280883 · Cited by 31,502
Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex
Sarbassov, D. D., Guertin, D. A., Ali, S. M., & Sabatini, D. M. (2005) · Science · doi:10.1126/science.1106148 · Cited by 6,216
Cani, P. D., Bibiloni, R., Knauf, C., Waget, A., Neyrinck, A. M., Delzenne, N. M., & Burcelin, R. (2008) · Diabetes · doi:10.2337/db07-1403 · Cited by 4,819 · cited 16×
“Although NAFLD is benign, recent studies indicate that around 40% of NAFLD patients progress to fibrosis and .50% develop NASH after 4–13 years [2,3].”
BackgroundInfluentialAMPK regulates energy expenditure by modulating NAD+ metabolism and SIRT1 activity
Cantó, C., Gerhart-Hines, Z., Feige, J. N., Lagouge, M., Noriega, L., Milne, J. C., Elliott, P. J., Puigserver, P., & Auwerx, J. (2009) · Nature · doi:10.1038/nature07813 · Cited by 3,300
Kim, D.-H., Sarbassov, D. D., Ali, S. M., King, J. E., Latek, R. R., Erdjument-Bromage, H., Tempst, P., & Sabatini, D. M. (2002) · Cell · doi:10.1016/s0092-8674(02)00808-5 · Cited by 2,986
Human nutrition, the gut microbiome and the immune system
Kau, A. L., Ahern, P. P., Griffin, N. W., Goodman, A. L., & Gordon, J. I. (2011) · Nature · doi:10.1038/nature10213 · Cited by 2,588
Evolution of inflammation in nonalcoholic fatty liver disease: The multiple parallel hits hypothesis
Tilg, H., & Moschen, A. R. (2010) · Hepatology · doi:10.1002/hep.24001 · Cited by 2,548
Inflammasome-mediated dysbiosis regulates progression of NAFLD and obesity
Henao-Mejia, J., Elinav, E., Jin, C., Hao, L., Mehal, W. Z., Strowig, T., Thaiss, C. A., Kau, A. L., Eisenbarth, S. C., Jurczak, M. J., et al. (2012) · Nature · doi:10.1038/nature10809 · Cited by 2,435
Prolonged Rapamycin Treatment Inhibits mTORC2 Assembly and Akt/PKB
Sarbassov, D. D., Ali, S. M., Sengupta, S., Sheen, J.-H., Hsu, P. P., Bagley, A. F., Markhard, A. L., & Sabatini, D. M. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.029 · Cited by 2,365
Long-term follow-up of patients with NAFLD and elevated liver enzymes
Ekstedt, M., Franzén, L. E., Mathiesen, U. L., Thorelius, L., Holmqvist, M., Bodemar, G., & Kechagias, S. (2006) · Hepatology · doi:10.1002/hep.21327 · Cited by 2,302
Cited by
Short-chain fatty acids in control of body weight and insulin sensitivity
Canfora, E. E., Jocken, J. W., & Blaak, E. E. (2015) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2015.128 · Cited by 2,298
Antioxidant Properties of Probiotic Bacteria
Wang, Y., Wu, Y., Wang, Y., Xu, H., Mei, X., Yu, D., Wang, Y., & Li, W. (2017) · Nutrients · doi:10.3390/nu9050521 · Cited by 917
Singh, V., Lee, G., Son, H., Koh, H., Kim, E. S., Unno, T., & Shin, J.-H. (2023) · Frontiers in Microbiology · doi:10.3389/fmicb.2022.1103836 · Cited by 705
Butyrate reduces appetite and activates brown adipose tissue via the gut-brain neural circuit
Li, Z., Yi, C.-X., Katiraei, S., Kooijman, S., Zhou, E., Chung, C. K., Gao, Y., van den Heuvel, J. K., Meijer, O. C., Berbée, J. F. P., et al. (2018) · Gut · doi:10.1136/gutjnl-2017-314050 · Cited by 674
Feng, T., & Wang, J. (2020) · Gut Microbes · doi:10.1080/19490976.2020.1801944 · Cited by 621
De novo lipogenesis in the liver in health and disease: more than just a shunting yard for glucose
Sanders, F. W. B., & Griffin, J. L. (2016) · Biological Reviews · doi:10.1111/brv.12178 · Cited by 539
Takaki, A., Kawai, D., & Yamamoto, K. (2013) · International Journal of Molecular Sciences · doi:10.3390/ijms141020704 · Cited by 447
Nonalcoholic fatty liver disease and chronic vascular complications of diabetes mellitus
Targher, G., Lonardo, A., & Byrne, C. D. (2018) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2017.173 · Cited by 397
Cui, X., Ye, L., Li, J., Jin, L., Wang, W., Li, S., Bao, M., Wu, S., Li, L., Geng, B., et al. (2018) · Scientific Reports · doi:10.1038/s41598-017-18756-2 · Cited by 374
Role of gut microbiota and Toll-like receptors in nonalcoholic fatty liver disease
Miura, K. (2014) · World Journal of Gastroenterology · doi:10.3748/wjg.v20.i23.7381 · Cited by 355
Gut–liver axis, nutrition, and non-alcoholic fatty liver disease
Kirpich, I. A., Marsano, L. S., & McClain, C. J. (2015) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2015.06.023 · Cited by 327
“butyrate-producing probiotic, prevents progression of choline-deficient/L-amino acid-defined (CDAA)-diet-induced NAFLD and tumorigenesis in rats [92].”
BackgroundJia, L., Li, D., Feng, N., Shamoon, M., Sun, Z., Ding, L., Zhang, H., Chen, W., Sun, J., & Chen, Y. Q. (2017) · Scientific Reports · doi:10.1038/s41598-017-07335-0 · Cited by 179
Fructans: Prebiotics and immunomodulators
Peshev, D., & Van den Ende, W. (2014) · Journal of Functional Foods · doi:10.1016/j.jff.2014.04.005 · Cited by 175
Probiotics as Complementary Treatment for Metabolic Disorders
Le Barz, M., Anhê, F. F., Varin, T. V., Desjardins, Y., Levy, E., Roy, D., Urdaci, M. C., & Marette, A. (2015) · Diabetes & Metabolism Journal · doi:10.4093/dmj.2015.39.4.291 · Cited by 142
Cavaleri, F., & Bashar, E. (2018) · Journal of Nutrition and Metabolism · doi:10.1155/2018/7195760 · Cited by 126
Betrapally, N. S., Gillevet, P. M., & Bajaj, J. S. (2016) · Gastroenterology · doi:10.1053/j.gastro.2016.02.073 · Cited by 123
Tsao, S.-P., Nurrahma, B. A., Kumar, R., Wu, C.-H., Yeh, T.-H., Chiu, C.-C., Lee, Y.-P., Liao, Y.-C., Huang, C.-H., Yeh, Y.-T., et al. (2021) · Antioxidants · doi:10.3390/antiox10111823 · Cited by 79
Chen, Y., Lin, Y., Lin, J., Yang, N., & Chen, M. (2018) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201700903 · Cited by 77
Pataky, Z., Genton, L., Spahr, L., Lazarevic, V., Terraz, S., Gaïa, N., Rubbia-Brandt, L., Golay, A., Schrenzel, J., & Pichard, C. (2016) · Digestive Diseases and Sciences · doi:10.1007/s10620-016-4179-1 · Cited by 75
“In animals, butyrate-producing bacteria have been shown to improve NAFLD [45] and butyrate treatment to prevent diet-induced obesity in animals [46].”
BackgroundCalorie restriction and its impact on gut microbial composition and global metabolism
Zheng, X., Wang, S., & Jia, W. (2018) · Frontiers of Medicine · doi:10.1007/s11684-018-0670-8 · Cited by 65
Allan, N. P., Yamamoto, B. Y., Kunihiro, B. P., Nunokawa, C. K. L., Rubas, N. C., Wells, R. K., Umeda, L., Phankitnirundorn, K., Torres, A., Peres, R., et al. (2024) · Nutrients · doi:10.3390/nu16101401 · Cited by 44
“Notably, the gut-produced short chain fa tt y acid However, the exact mechanism by which gut flora interact with hepatically derived ketone bodies remains less understood. butyrate shares similarities with β -hydroxybutyrate and has been considered as a potential supplement for ASD [14–17].”
BackgroundShida, Y., Endo, H., Owada, S., Inagaki, Y., Sumiyoshi, H., Kamiya, A., Eto, T., & Tatemichi, M. (2021) · Scientific Reports · doi:10.1038/s41598-021-02591-7 · Cited by 6
Self-citation
Metadata
- Authors
- Endo, H., Niioka, M., Kobayashi, N., Tanaka, M., & Watanabe, T.
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2013-05-16
- Volume
- 8
- Issue
- 5
- Pages
- e63388
- ISSN
- 1932-6203 (ISSN-L)
- OpenAlex
- W2083725282
- Cited by
- 336
- References
- 64
- FWCI
- 14.49
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.